English | 简体中文 | LP ACCESS

About artrix

This author has not yet filled in any details.
So far artrix has created 55 blog entries.

Vivo Capital’s venture portfolio company AADI announces a merger agreement with Aerpio Pharmaceuticals with a concurrent $155M in PIPE financing by Aerpio Pharmaceuticals

Vivo Capital’s venture portfolio company AADI announces a merger agreement with Aerpio Pharmaceuticals with a concurrent $155M in PIPE financing by Aerpio Pharmaceuticals2021-05-22T13:33:43-07:00

Vivo Capital and an Investor Syndicate Completes Sale of Surgical Specialties Corporation to GTCR-backed Corza Health

Vivo Capital and an Investor Syndicate Completes Sale [...]

Vivo Capital and an Investor Syndicate Completes Sale of Surgical Specialties Corporation to GTCR-backed Corza Health2021-02-08T23:04:27-08:00

Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)!

Congratulations to Prof. Frances Arnold, the first American [...]

Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)!2021-01-18T20:57:50-08:00

Vivo Portfolio Company, Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARROTM) in Greater China

Vivo Portfolio Company, Aadi Bioscience and EOC Pharma [...]

Vivo Portfolio Company, Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARROTM) in Greater China2021-01-14T20:40:39-08:00

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

VISEN Pharmaceuticals Closes $150 Million Series B Financing [...]

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China2021-01-10T08:39:07-08:00

Palo Alto
Global Headquarters

Beijing
 

Shanghai 
 

Taipei  
 

Hong Kong   
 

Email: info@vivocapital.com
Vivo Capital®, SEC registered, effective 6/19/2014. All rights reserved.
Go to Top